A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis

Main Article Content

Matthew Zirwas
Zoe Draelos
Janet Dubois
Leon Kircik
Angela Moore
Linda Stein Gold
Javier Alonso-Llamazares
Michael Bukhalo
Suzanne Bruce
Kimmie Eads
Lawrence Green
Scott Guenthner
Laura Ferris
Seth Forman
Steven Kempers
Edward Lain
Charles Lynde
David Pariser
David Pariser
Darryl Toth
paul Yamauchi
Patrick Burnett
David Berk

Keywords

roflumilast, seborrheic dermatitis, phase 2a study

Abstract

N/A

References

1. Araya M, et al. Indian J Dermatol 2015;60:519.

2. Pärna E, et al. Acta Derm Venereol 2015; 95:312-316.

3. Clark GW, et al. Am Fam Physician 2015;91:185-190.

4. Kastarinen H, et al. Cochrane Database Syst Rev 2014:CD009446.

5. Peyrí J, et al. Actas Dermosifiliogr 2007;98:476-482. 6. Lebwohl MG, et al. N Engl J Med 2020;383:229-239

Most read articles by the same author(s)

<< < 5 6 7 8 9 10 11 12 > >>